Episodes 1-15 of 26
Decoding Gene Therapy for Hemophilia B: Expert Insights on Common Myths
Medical Industry FeatureDecoding Gene Therapy for Hemophilia B: Expert Insights on Common Myths
Evaluating First-Line Therapy for Acute
Graft-Versus-Host DiseaseMedical Industry FeatureEvaluating First-Line Therapy for Acute
Graft-Versus-Host DiseaseUpgrade Your Adult Patients’ IgAN Treatment
Medical Industry FeatureUpgrade Your Adult Patients’ IgAN Treatment
CV Risk in Patients with Narcolepsy: See the Data
Medical Industry FeatureCV Risk in Patients with Narcolepsy: See the Data
Identifying Patients at High-Risk for IgAN Progression: Key Factors to Know
Medical Industry FeatureIdentifying Patients at High-Risk for IgAN Progression: Key Factors to Know
IgAN Insights: The Potential Role of the Complement System in Disease Progression
Medical Industry FeatureIgAN Insights: The Potential Role of the Complement System in Disease Progression
Managing the Complexities of Acute Graft-Versus-Host Disease: Current Challenges and Unmet Needs
Medical Industry FeatureManaging the Complexities of Acute Graft-Versus-Host Disease: Current Challenges and Unmet Needs
The CLL Patient Journey: From Diagnosis to Initial Treatment
Medical Industry FeatureThe CLL Patient Journey: From Diagnosis to Initial Treatment
Navigating CLL Treatment: Patient Preferences and Shared Decision-Making
Medical Industry FeatureNavigating CLL Treatment: Patient Preferences and Shared Decision-Making
Advancements in Understanding ALS Treatment
Medical Industry FeatureAdvancements in Understanding ALS Treatment
Gene Therapy: Changing the Landscape of Hemophilia B Care
Medical Industry FeatureGene Therapy: Changing the Landscape of Hemophilia B Care
Investigating a gMG Therapy, Part 1: The MG-ADL Results
Medical Industry FeatureInvestigating a gMG Therapy, Part 1: The MG-ADL Results
From Symptoms to Diagnosis: Navigating ATTR Amyloidosis in Clinical Practice
Medical Industry FeatureFrom Symptoms to Diagnosis: Navigating ATTR Amyloidosis in Clinical Practice
Investigating a gMG Therapy, Part 2: The Secondary Endpoint Results, Including MG Symptoms PRO
Medical Industry FeatureInvestigating a gMG Therapy, Part 2: The Secondary Endpoint Results, Including MG Symptoms PRO
Investigating a gMG Therapy, Part 3: Results from the Extension Studies
Medical Industry FeatureInvestigating a gMG Therapy, Part 3: Results from the Extension Studies
